Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChAdOx1 + MVA
- Development stage
- Unknown
- Lead developer
- University of Oxford
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ChAdOx1 + MVA refers to a heterologous prime-boost vaccination regimen that combines two viral vectors—ChAdOx1 (chimpanzee adenovirus Oxford 1) and Modified Vaccinia Ankara (MVA)—to deliver antigens for the prevention or treatment of infectious diseases or cancer. The approach is designed to induce robust cellular and humoral immune responses by priming with the adenoviral vector (ChAdOx1) and boosting with the poxviral vector (MVA). This platform has been used in vaccines targeting HIV-1 (HIVconsvX), hepatitis B virus (HBV), prostate cancer (targeting antigen 5T4), tuberculosis (antigen 85A), malaria, and Middle East respiratory syndrome coronavirus (MERS-CoV). The mechanism of action is immunostimulation via delivery of disease-specific antigens to elicit strong T-cell responses—especially CD8+ cytotoxic T cells—and antibody production. Multiple clinical trials have demonstrated safety and immunogenicity in humans[1][2][3][4][5][6][7][8].
- Other names
- ChAdOx1-MVA 5T4 vaccineChAdOx-1-MVA 5T4 vaccineChAdOx 1-MVA 5T4 vaccineVTP-800VTP800VTP 800
02
Targets
ACE2 (Angiotensin-converting enzyme 2)SARS-CoV-2 spike
Beyond the preview
Go deeper on ChAdOx1 + MVA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChAdOx1 + MVA.